These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11555892)

  • 21. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.
    Wu B; Moulton HM; Iversen PL; Jiang J; Li J; Li J; Spurney CF; Sali A; Guerron AD; Nagaraju K; Doran T; Lu P; Xiao X; Lu QL
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14814-9. PubMed ID: 18806224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene therapy for duchenne muscular dystrophy: expectations and challenges.
    Rodino-Klapac LR; Chicoine LG; Kaspar BK; Mendell JR
    Arch Neurol; 2007 Sep; 64(9):1236-41. PubMed ID: 17846262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene therapy progress and prospects: Duchenne muscular dystrophy.
    Foster K; Foster H; Dickson JG
    Gene Ther; 2006 Dec; 13(24):1677-85. PubMed ID: 17066097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent inotrope infusion for end stage heart failure in Duchenne muscular dystrophy.
    van Baalen A; von Spiczak S; Stephani U; Fischer G
    Neuromuscul Disord; 2008 Dec; 18(12):1005-6; author reply 1006. PubMed ID: 18952428
    [No Abstract]   [Full Text] [Related]  

  • 26. Two-tiered hypotheses for Duchenne muscular dystrophy.
    Grounds MD
    Cell Mol Life Sci; 2008 Jun; 65(11):1621-5. PubMed ID: 18327663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy.
    Lai Y; Li D; Yue Y; Duan D
    Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Full-length dystrophin gene transfer to the mdx mouse in utero.
    Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
    Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Duchenne muscular dystrophy: perspectives of treatment].
    Palmieri B; Sblendorio V
    Recenti Prog Med; 2006 Sep; 97(9):448-58. PubMed ID: 17017294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy.
    Guo C; Willem M; Werner A; Raivich G; Emerson M; Neyses L; Mayer U
    Hum Mol Genet; 2006 Mar; 15(6):989-98. PubMed ID: 16476707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new lease on life for patients with Duchenne muscular dystrophy in Japan.
    Yasuma F; Konagaya M; Sakai M; Kuru S; Kawamura T
    Am J Med; 2004 Sep; 117(5):363. PubMed ID: 15336589
    [No Abstract]   [Full Text] [Related]  

  • 35. Technology insight: therapy for Duchenne muscular dystrophy-an opportunity for personalized medicine?
    Lim LE; Rando TA
    Nat Clin Pract Neurol; 2008 Mar; 4(3):149-58. PubMed ID: 18268530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modification of pre-mRNA processing: application to dystrophin expression.
    Wilton SD; Fletcher S
    Curr Opin Mol Ther; 2006 Apr; 8(2):130-5. PubMed ID: 16610765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetics. Hopping to a better protein.
    Pennisi E
    Science; 2008 Dec; 322(5907):1454-5. PubMed ID: 19056949
    [No Abstract]   [Full Text] [Related]  

  • 38. Proximal dystrophin gene deletions and protein alterations in becker muscular dystrophy.
    Novaković I; Bojić D; Todorović S; Apostolski S; Luković L; Stefanović D; Milasin J
    Ann N Y Acad Sci; 2005 Jun; 1048():406-10. PubMed ID: 16154963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continued need for caution in the diagnosis of Duchenne muscular dystrophy.
    Griggs RC; Bushby K
    Neurology; 2005 May; 64(9):1498-9. PubMed ID: 15883307
    [No Abstract]   [Full Text] [Related]  

  • 40. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
    J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.